Description
Humana Press Inc. Antimalarial Chemotherapy Mechanisms Of Action Resistance And New Directions In Drug Discovery by Philip J. Rosenthal
Philip Rosenthal, MD, and a panel of leading malaria experts drawn from academia, the military, and international health organizations survey the latest scientific understanding of antimalarial chemotherapy, emphasizing the molecular mechanisms of resistance and the description of important new targets. Their survey covers the current status of malarial and antimalarial chemotherapy, the relevant biology and biochemistry of malaria parasites, the antimalarial drugs currently available, new chemical approaches to chemotherapy, and possible new targets for chemotherapy. Comprehensive and cutting-edge, Antimalarial Chemotherapy: Mechanisms of Action, Resistance, and New Directions in Drug Discovery clearly delineates all the basic and clinical research now addressing one of the world's major unresolved disease problems, work that is now powerfully driving the rapid pace of antimalarial drug discovery today.
I. Introduction
The Need for New Approaches to Antimalarial Chemotherapy
Philip J. Rosenthal and Louis H. Miller
The History of Antimalarial Drugs
Steven R. Meshnick and Mary J. Dobson
Transport and Trafficking in Plasmodium-Infected Red Cells
Kasturi Haldar and Thomas Akompong
The Plasmodium Food Vacuole
Ritu Banerjee and Daniel E. Goldberg
Clinical and Public Health Implications of Antimalarial Drug Resistance
Piero L. Olliaro and Peter B. Bloland
II. Established Antimalarial Drugs and Compounds Under Clinical Development
Chloroquine and Other Quinoline Antimalarials
Leann Tilley, Paul Loria, and Mick Foley
8-Aminoquinolines
Ralf P. Brueckner, Colin Ohrt, J. Kevin Baird, and Wilbur K. Milhous
Mechanisms of Quinoline Resistance
Grant Dorsey, David A. Fidock, Thomas E. Wellems, and Philip J. Rosenthal
Folate Antagonists and Mechanisms of Resistance
Christopher V. Plowe
Artemisinin and Its Derivatives
Steven R. Meshnick. Atovaquone-Proguanil Combination, Akhil B. Vaidya
The Antimalarial Drug Portfolio and Research Pipeline
Piero L. Olliaro and Wilbur K. Milhous
III. New Compounds, New Approaches, and New Targets
Novel Quinoline Antimalarials
Paul A. Stocks, Kaylene J. Raynes, and Stephen A. Ward
New Antimalarial Trioxanes and Endoperoxides
Gary H. Posner, Mikhail Krasavin, Michael McCutchen, Poonsakdi Ploypradith, John P. Maxwell, Jeffrey S. Elias, and Michael H. Parker
Antibiotics and the Plasmodial Plastid Organelle
Barbara Clough and R. J. M. (Iain) Wilson
Fresh Paradigms for Curative Antimetabolites
Pradipsinh K. Rathod. Iron Chelators, Mark Loyevsky and Victor R. Gordeuk
Protease Inhibitors
Philip J. Rosenthal
Inhibitors of Phospholipid Metabolism
Henri Joseph Vial and Michele Calas
Development of New Malaria Chemotherapy by Utilization of Parasite-Induced Transport
Annette M. Gero and Alexander L. Weis